Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
81.44
+2.27 (+2.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
7 Dividend Stocks to Invest In for a Lifetime of Income
June 05, 2024
Discover top dividend stocks to buy for 2024 to maximize profits and minimize risks in today’s investing environment.
Via
InvestorPlace
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
June 04, 2024
The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender women and people who inject drugs. These mid-stage studies will evaluate...
Via
Benzinga
3 Dividend Stocks That Even Ken Griffin Is Buying
June 04, 2024
Billionaire investor Ken Griffin is filling the portfolio of his Citadel Advisors hedge fund with dividend paying stocks.
Via
InvestorPlace
Large Cap BIopharmaceuticals Overview
June 03, 2024
As a defensive play healthcare is weighted at about 12% of the S&P 500.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
June 03, 2024
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response...
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
May 21, 2024
Via
Benzinga
Market Whales and Their Recent Bets on GILD Options
May 15, 2024
Via
Benzinga
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
May 10, 2024
Via
Benzinga
Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer
May 31, 2024
Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but showed...
Via
Benzinga
Is Nvidia Worth 35x Times Sales, History Says No
May 29, 2024
You wouldn’t be able to tell just by looking at the S&P 500 daily change of +0.02%, but Tuesday was a pretty negative day, with the S&P 500 equal weight RSP ETF finishing down by almost 70 bps.
Via
Talk Markets
Topics
ETFs
Stocks
Exposures
US Equities
2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years
May 28, 2024
These companies have grown their dividends despite some troubles.
Via
The Motley Fool
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
Via
InvestorPlace
3 Biotech Stocks to Buy Now: May 2024
May 22, 2024
As the biotech industry continues to rise in market prominence, investors should start considering what the best biotech stocks to buy are.
Via
InvestorPlace
Why NASDAQ:GILD qualifies as a good dividend investing stock.
May 09, 2024
Why GILEAD SCIENCES INC (NASDAQ:GILD) is a Top Pick for Dividend Investors.
Via
Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,300 Today
May 07, 2024
Via
Benzinga
Gilead Sciences Unusual Options Activity For May 06
May 06, 2024
Via
Benzinga
Large Cap Biopharmaceuticals Performance
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
May 20, 2024
Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant improvements in cholestasis markers and pruritus.
Via
Benzinga
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
May 16, 2024
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns.
Via
InvestorPlace
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.
Via
InvestorPlace
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
May 06, 2024
If you want your shot at significant upside, speculate on these stocks near 52-week lows that can prove the critics wrong.
Via
InvestorPlace
How Is The Market Feeling About Gilead Sciences?
May 06, 2024
Via
Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gilead Sciences Unusual Options Activity
April 26, 2024
Via
Benzinga
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
May 01, 2024
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May.
Via
InvestorPlace
3 Dividend Stocks to Buy at a 52-Week Low in April
April 26, 2024
Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors.
Via
InvestorPlace
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
April 25, 2024
GILD earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024
April 25, 2024
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss?
April 25, 2024
Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury.
Via
Investor's Business Daily
Exposures
COVID-19
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
April 25, 2024
Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.